Our analysis indicates that ALGN’s North American GP utilization is expected to remain soft in the second quarter of 2024, potentially resulting in a slight revenue miss. This could serve as a significant catalyst for a short position, especially following the company’s recent guidance upgrade for 2024.
Our focus on discretionary medical spending has led us to expand beyond our short position in EYE by adding PDCO to our portfolio. We believe that ALGN is a compelling short opportunity going into the second half of 2024 for various reasons.
The correlation between ALGN shares and EPS estimates is quite strong, with a seeming resistance at a 20X forward P/E multiple. However, we anticipate a more subdued outlook for the second half of 2024, along with increasing macroeconomic uncertainties and lower 2025 estimates, to potentially break this resistance level. In such a scenario, ALGN could drop below $200, representing a potential decline of 20% from its current level.
Red meat, fruit juice consumption, and a sedentary lifestyle are all risk factors for prediabetes.…
Jordan's economy is facing external shocks that have affected its growth and job creation, despite…
In the upcoming elections in the United Kingdom, a growing group of pro-Palestinian candidates are…
In a groundbreaking discovery, researchers have found that Florida carpenter ants possess the ability to…
In the recent European Championship knockout stage match between Turkey and Austria, Arda Guler made…
Gazpacho soup is a delicious and nutritious option that has numerous health benefits. It contains…